Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, announces it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis. Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life.
Read the full article: Mariana Oncology to Be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer //
Source: https://www.businesswire.com/news/home/20240502315526/en/Mariana-Oncology-to-be-Acquired-by-Novartis-to-Advance-Precision-Radiopharmaceuticals-to-Treat-Cancer